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Abstract
Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer’s
disease (AD). It is now recognized that pathophysiological changes begin many years prior to clinical manifestations
of disease and the spectrum of AD spans from clinically asymptomatic to severely impaired. Defining AD purely by
its clinical presentation is thus artificial and efforts have been made to recognize the disease based on both clinical
and biomarker findings. Advances with biomarkers have also prompted a shift in how the disease is considered as a
clinico-pathophysiological entity, with an increasing appreciation that AD should not only be viewed with discrete
and defined clinical stages, but as a multifaceted process moving along a seamless continuum. Acknowledging this
concept is critical to understanding the development process for disease-modifying therapies, and for initiating
effective diagnostic and disease management options. In this article, we discuss the concept of a disease
continuum from pathophysiological, biomarker, and clinical perspectives, and highlight the importance of
considering AD as a continuum rather than discrete stages. While the pathophysiology of AD has still not been
elucidated completely, there is ample evidence to support researchers and clinicians embracing the view of a
disease continuum in their study, diagnosis, and management of the disease.
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Background
In the century since Alois Alzheimer discovered
Alzheimer’s disease (AD), scientists have made re-
markable strides in understanding the illness [1], al-
though it was not until the 1980s that two key
molecular culprits in disease pathophysiology, amyl-
oid beta (Aβ) and tau proteins, were identified [2, 3].
Historically, the clinical definition of AD was consid-
ered probable because it was based on the systematic ex-
clusion of other potential etiologies in a patient with a
dementia syndrome and not on positive proof of AD
pathology. Thus, AD could be confirmed only through
postmortem findings or, rarely, in life by brain biopsy.
Later, AD was defined in a broader sense based on clin-
ical manifestations. With basic research advances in re-
cent years, it is now recognized that, like many chronic
diseases, pathophysiological changes begin many years
prior to clinical manifestations of disease such that the
spectrum of AD spans from clinically asymptomatic to
severely impaired. As a result, defining AD purely by its
clinical presentation is artificial and efforts have been
made to recognize the disease based on both clinical and
biomarker findings.
Advances with biomarkers have prompted a shift in
how the disease is considered as a clinico-
pathophysiological entity, with an increasing appreci-
ation that AD should not be viewed with discrete and
defined clinical stages, but as a multifaceted process
moving along a continuum. Appreciating this concept is
critical to understanding the distinction between AD
and AD dementia, in order to initiate effective diagnostic
and disease management options and for the develop-
ment of effective disease-modifying therapies (DMTs).
The aim of this article is to discuss how our under-
standing of AD pathophysiology and the currently avail-
able biomarkers and clinical tools can assist with
creating a more uniform approach (in both research and
clinical practice) to conceptualizing AD as a continuum.
This will help set the stage for the future management
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of AD and help lay a foundation for the prevention or
effective treatment of AD by 2025, the year set by global
leaders as the target for finding an effective way to treat
or prevent AD [4].
Understanding the disease continuum
Based on currently available information, AD is best
conceptualized as a biological and clinical continuum
covering both the preclinical (clinically asymptomatic in-
dividuals with evidence of AD pathology) and clinical
(symptomatic) phases of AD. In the broadest sense, a
continuum is defined as a seamless sequence in which
adjacent elements (severities) are not perceptibly differ-
ent from each other, although the extremes are distinct.
In AD, this equates to disease progression from an
asymptomatic phase, through a long preclinical period
during which pathophysiological changes are reflected
by increasing biomarker evidence of disease, to the
symptomatic phase, during which biomarker changes
continue and symptoms of cognitive and then functional
impairment become increasingly evident, with the even-
tual loss of independence and death. These changes in
the individual components of the continuum occur in a
sequential but overlapping manner.
Disease etiology and pathophysiology
The etiology of AD is complex and much remains to be
fully elucidated. The close link between genetic muta-
tions and disorders associated with AD (mutations of
presenilin 1 (PS1), presenilin 2 (PS2), amyloid beta pre-
cursor protein (APP), and Trisomy 21) and the accumu-
lation of Aβ strongly implicates this molecule as a
pathological driver in AD, but there is controversy over
whether Aβ accumulation alone indicates inevitable pro-
gression to AD. Furthermore, evidence indicates that Aβ
accumulation alone is probably insufficient to produce
symptoms [5–7]. At some point during the disease
course, additional factors are involved in determining re-
gional neurodegeneration [8]. Tau pathology has been
suggested as a facilitator of the downstream effects of
amyloid [9]. Other investigators have proposed that syn-
aptic, mitochondrial, metabolic, inflammatory, neuronal,
cytoskeletal, myelin, and other age-related alterations
may also play a role in the pathogenesis of AD [10].
Based on our current understanding, histopathological
characteristics of AD include 1) accumulation of amyloid
plaques—extracellular deposition of Aβ protein, both dif-
fuse plaques of amorphous, primarily nonfibrillar Aβ ag-
gregates and neuritic plaques of fibrillar Aβ arranged in a
β-pleated conformation; 2) formation of neurofibrillary
tangles (NFTs)—intraneuronal bundles of aggregated tau
protein, including hyperphosphorylated tau (p-tau), form-
ing paired helical filaments that aggregate within the neu-
rons to create NFTs, leading to disruption of microtubule
function, impaired axonal transport, and synaptic and
neuronal injury; and 3) neurodegeneration—progressive
loss of neurons or their processes (axons and dendrites)
with a corresponding progressive impairment in neuronal
function and loss of neurons and synapses (atrophy) [11].
Of note, these features individually are not diagnostic of
AD. Several lines of evidence currently suggest that in
AD the interplay between Aβ and tau is such that Aβ
can drive tau pathology and tau pathology may drive
Aβ pathology [12, 13]. Our understanding of the
pathophysiology of AD is further complicated by pri-
mary age-related tauopathy (PART) [14, 15], a neuro-
pathological condition revealed by tau imaging. PART
is characterized by medial–temporal neurofibrillary
pathology; the pathology remains localized and there
are few or no Aβ deposits.
The transition between healthy aging and preclinical
AD is not well defined, at least with our current un-
derstanding. This shift is likely subtle and without
discernible steps; one can suppose that a combination
of genetic and environmental factors plays a role in
the process [16]. Genetic factors that may contribute
as disease modifiers include the apolipoprotein pro-
tein E epsilon 4 (APOE4) allele, which conveys an in-
creased risk of disease, and more rapid cognitive
decline in the setting of early AD pathology [17].
Other factors that may play a role include cardiovas-
cular risk factors and lifestyle factors such as diet,
physical exercise, and cognitive engagement. These
lifestyle characteristics influence “cognitive reserve”
and onset of objective cognitive decline [18]. The
concept of brain or cognitive reserve was originally
invoked to provide an explanation for the observation
that the extent of AD histopathological changes at
autopsy did not always align with the degree of clin-
ical impairment. “Brain reserve” refers to the capacity
of the brain to withstand pathological insult, perhaps
because of greater synaptic density or a larger num-
ber of healthy neurons, such that sufficient neural
substrate remains to support normal function. “Cogni-
tive reserve” is thought to represent the ability to en-
gage alternate brain networks or cognitive strategies
to cope with the effects of encroaching pathology.
While cognitive reserve may help delay the onset of
clinical symptoms, once symptoms do emerge the rate
of impairment may be greater [18] (i.e., there is a
steeper trajectory for clinical impairment) because,
while clinical symptoms are delayed, pathological
changes progress.
The challenges in elucidating when pathophysio-
logical changes start in the brain make it difficult to
define a time of disease onset. Findings from epide-
miologic studies suggest that midlife or earlier expo-
sures (e.g., hypertension, smoking, diabetes, and
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obesity) increase the risk for subsequent clinically di-
agnosed AD dementia [19–21]. Available data are
largely cross-sectional, although long-term popula-
tion studies also provide evidence to suggest that
late-life dementia may be linked to exposures occur-
ring in early and midlife; these studies have not fo-
cused on AD specifically, and biomarkers were not
considered. Recently initiated prospective cohort
studies such as the PREVENT Project [22] will yield
important information on the interplay between risk
factors, biological and clinical changes, and the se-
quence of disease processes. Based on what we know
today about AD pathophysiology and the sensitivity
of currently available biomarkers, the starting point
of disease is generally defined as when there is spe-
cific biomarker evidence of disease, more specifically
the demonstration of Aβ accumulation, as revealed
by positron emission tomography (PET) or cerebro-
spinal fluid (CSF) analysis (Table 1).
Biomarker and clinical findings along the
continuum
The AD continuum is composed of multiple intercon-
nected components (pathophysiological processes, bio-
marker findings, and clinical symptoms), each occurring
on its own trajectory, with individual trajectories gener-
ally parallel to each other but with some temporal off-
sets. The trajectories are influenced by modulating
factors and, for both biomarkers and clinical symptoms,
are dependent upon the sensitivity of the measurement.
The preclinical phase of AD
Exploring the continuum through the preclinical
phase requires the use of biomarkers because
Table 1 Biomarkers currently in use in the AD field
Biomarker Findings in AD
– other relevant notes
CSF analysis
Aβ1–42 Reduced concentration
– Measures soluble forms of Aβ
– Result of equilibrium shifts due to deposition/aggregation of Aβ1–42 in brain parenchyma or decreased
production of Aβ1–42
– Level inversely reflects brain Aβ burden
t-tau, p-tau Increased concentrations
– t-tau reflects the intensity of neuronal degeneration; it is elevated in other conditions such as head trauma,
CJD, and stroke and therefore not specific for AD
– p-tau is a marker of the abnormal pathophysiology associated with neurofibrillary tangle pathology
(hyperphosphorylation) in the brain. It is fairly specific for AD and is not elevated in primary tauopathies,
head injury, or stroke
PET scana
Amyloid PET Retention of amyloid tracer
– Amyloid tracers include 11C-PiB, florbetapir (AV-45), 91 flutemetamol (18F-PiB derivative), florbetaben (AV-1),
and AZD4694
– Identifies fibrillar Aβ and provides information about extent of Aβ plaque burden in brain
FDG PET Evidence of reduced temporo-parietal glucose metabolism
– Flurodeoxyglucose (18F) tracer
– Sensitive marker of synaptic dysfunction
Tau PET Retention of tau tracer
– Tau tracers include flortaucipir (18 F-AV1451). Others are in development
MRI
fMRI Measure of function
– Detects differences in BOLD signals over time and space
– Task-associated/based fMRI measures spatio-temporal changes in BOLD signal associated with administration
of a task during the scan
– Resting state fMRI measures spatio-temporal correlations in intrinsic or spontaneous fluctuation of BOLD signal
– Used to study functional networks (e.g., the default mode network)
vMRI Volume or cortical thickness reduced
– Provides a measure of volume of whole brain, specific anatomical regions, or cortical thickness
– Demonstrates medial temporal atrophy and, more specifically, hippocampal atrophy; hippocampal volume is
reduced in many conditions, including old age, and several neurodegenerative disorders as well as
nonneurodegenerative disorders (e.g., diabetes, sleep apnea, bipolar disorder)
Aβ amyloid beta, AD Alzheimer’s disease, CSF cerebrospinal fluid, t-tau total tau, p-tau phosphorylated tau, FDG flurodeoxyglucose, PiB Pittsburgh compound B,
PET positron emission tomography, MRI magnetic resonance imaging, fMRI functional MRI, vMRI volumentric MRI, BOLD blood oxygen level dependent, CJD
Creutzfeldt-Jakob disease
aUses specific ligands to detect AD pathophysiology in the brain
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individuals are apparently clinically normal. A num-
ber of diagnostic and progression markers have
been described (Table 1), with the distinction being
that diagnostic biomarkers are direct surrogates of
brain AD lesions (amyloidosis or tauopathy) and
therefore indicative of the presence of the disease,
irrespective of stage, while progression markers
identify downstream changes (metabolic changes,
neuronal loss with atrophy) indicative of disease
progression but not necessarily specific to AD [23].
Biomarker trajectories paralleling the hypothetical
pathophysiological sequence of AD and specific bio-
marker changes over time were described by Jack et
al. [24, 25] (Fig. 1).
The model presents the temporal evolution of five
well-established AD biomarkers that provide a measure
of brain Aβ deposition, tau, or neurodegeneration both
in relation to each other and to the onset and progres-
sion of clinical symptoms. The model assumes that each
biomarker follows a nonlinear temporal course, which is
hypothesized to be sigmoid shaped, and that the max-
imum rate of change moves sequentially from one bio-
marker to the next. While there is some individual
variation, changes in markers of Aβ deposition generally
precede those of tau and neurodegeneration. The model
not only describes biomarker trajectories in the preclin-
ical phase, but also in the clinical phase, when symptoms
become evident. Support for this hypothetical model has
Fig. 1 Change in biomarkers over time. a Sequential change in measures of AD. Reproduced with permission from [24]. b Modified graph
showing that amyloid accumulation (measured as low CSF Aβ or elevated amyloid PET standard uptake value ratio) occurs first and functional
decline occurs late in the continuum of AD (as before), but cognitive performance, FDG-PET, tau PET, and MRI atrophy change along a common,
gradually steepening curve. Aβ amyloid beta, FDG flurodeoxyglucose, PET positron emission tomography, MCI mild cognitive impairment due to
Alzheimer’s disease
Aisen et al. Alzheimer's Research & Therapy  (2017) 9:60 Page 4 of 10
been provided by cross-sectional biomarker data across
the preclinical/clinical continuum [26–28].
The transition to the clinical phase of AD
Whether there is a specific threshold or regional distri-
bution of AD pathology and/or a specific combination
of biomarker abnormalities that will best predict the
emergence of clinical symptoms remains unclear. Cogni-
tive decline will likely occur only where there is Aβ ac-
cumulation plus other changes—synaptic dysfunction
and/or paired helical filament tangle formation, neuro-
degeneration, and neuronal loss [29, 30].
The time between Aβ accumulation and clinical symp-
toms remains to be quantified, but current theories sug-
gest that the onset of cognitive decline lags by at least 15
years [26, 31–33]. There are interindividual differences
and some older individuals with preclinical evidence of
pathophysiological changes may not become symptomatic
during their lifetime, potentially the result of a more
slowly progressing disease or death due to a competitive
mortality. These interindividual differences are attribut-
able to both environmental and genetic factors, including
brain reserve, cognitive reserve, and genetic polymor-
phisms, as well as coexisting pathologies (age-related brain
diseases) and medical comorbidities. As an example of the
role of genetic factors, one allele of APOE4 shifts the risk
curve for the disease to 5 years earlier, two copies of
APOE4 shift it 10 years earlier, and one copy of the
APOE2 allele shifts it 5 years later [34, 35].
The distinction between preclinical (asymptomatic)
and early clinical (symptomatic) disease is subtle, and
clinical manifestations of AD do not become apparent
abruptly. Individuals with preclinical AD exhibit longitu-
dinal decline on cognitive assessments even in the ab-
sence of clinically significant symptoms [17, 36]. Some
individuals are aware of subtle changes in cognitive
function before they are detectable using currently avail-
able measures of episodic memory, psychomotor speed,
verbal fluency, and concept formation [37–39].
Advancing along the clinical continuum
The clinical continuum includes trajectories for both
cognition and function, each of which could be divided
into further individual trajectories—for example, cogni-
tion includes trajectories of episodic memory, executive
function, and verbal fluency; and function includes tra-
jectories of both basic and complex activities of daily liv-
ing (ADLs). Based on our current ability to detect
deficits, cognition and function appear to decline on
temporally offset trajectories and cognitive impairment
precedes and predicts functional impairment [40].
While the concept of a continuum is biologically more
appropriate for characterization of the course of AD,
some degree of staging has been helpful for clinical
purposes; for example, assessing public health impact,
clinical research purposes (trial population selection),
standardized patient assessment and management in
clinical practice, and health service utilization studies.
Traditionally, the two key clinical stages have been con-
sidered mild cognitive impairment (MCI) due to AD, or
prodromal AD, and AD dementia, with dementia further
divided into mild, moderate, and severe [41–43]. How-
ever, terminology such as “mild AD” and “moderate AD”
is inaccurate—by the time an individual has mild or
moderate dementia, they are far along the continuum
and the disease has been present for many years,
highlighting the important distinction between the syn-
dromic and neuropathological diagnoses. In addition,
while clinical staging nomenclature infers a clear distinc-
tion between the various stages, in reality the process
progresses in a more continuous manner.
Whether or not one embraces clinical staging and the
distinction between MCI and dementia, what is clear is
that advancing along the clinical continuum there is pro-
gressive impairment of cognitive abilities and function.
Cognitive deficits are often first apparent in episodic
memory, and there is a specific profile of memory deficits,
the amnestic syndrome, of “hippocampal type” [23, 43],
characterized by diminished free and cued recall ability.
This profile has been shown to be highly predictive for the
presence of AD pathology [44]. Episodic memory loss is
followed by or accompanies executive dysfunction (e.g.,
impaired planning and anticipation or failures on tests
such as dual tasking and response inhibition), and lan-
guage and recognition difficulties. Functional impairment
is usually first apparent as subtle deficits in complex
ADLs, such as problems with medication intake, tele-
phone use, financial decisions, keeping appointments, and
using everyday technology [45]. Impairment in basic ADL
function (such as eating, dressing, and toileting) is generally
not apparent until further along the clinical continuum. In
a recurring theme, there are individual differences in rate of
cognitive and functional decline, and not all individuals will
progress to AD dementia or through the various AD
dementia severities during their lifetime.
Clinical implications of the continuum
For the clinician, applying the continuum concept of AD
raises several points of importance for counseling and
prognostic discussions. AD can be diagnosed without
dementia; an understanding of the biomarker changes is
equally important to understanding clinical manifesta-
tions; and an appreciation for the temporal course of
AD from preclinical biomarker evidence of disease
through the presence of clinical symptoms is critical for
effective disease diagnosis and management.
As 2025 approaches, there are other considerations
concerning the continuum concept. There is currently
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no cure available but if forthcoming new treatments in-
clude DMTs that may have more impact if initiated earl-
ier in the disease process, then earlier detection of
disease is necessary. For more effective disease manage-
ment, we also need to predict the future clinical course
of disease more accurately. To achieve these goals, more
research is needed to define biomarker profiles that best
predict progression from the preclinical to the clinical
stage and biomarker and/or cognitive profiles that best
predict progression and rate of progression along the
clinical course.
Role of biomarker assessment
While we know that pathological changes begin long be-
fore symptoms appear, determining whether biomarker
evidence of pathophysiological changes in the preclinical
stage implies definite progression to clinical disease dur-
ing an individual’s lifetime is difficult. Individual bio-
markers do not provide definitive prognostic
information. Recently, there have been efforts to im-
prove diagnostic accuracy and ability to predict those at
risk for clinical symptoms by considering a combination
of biomarker findings. Jack et al. [46] proposed that
diagnosis should be based on both the presence and ab-
sence of seven biomarkers in three categories (amyloid,
tau, and neurodegeneration (A/T/N)). Dubois et al. [47]
proposed that diagnosis be based on both Aβ and tau
pathology. Using these criteria, the authors went further
to differentiate between a “state” and a “stage”. In simple
terms, a state is considered asymptomatic at risk of AD
(cognitively normal and amyloid or tau positive but not
both) or AD (amyloid and tau positive), while a stage re-
fers to the degree of disease progression within a given
state (e.g., clinical AD, preclinical AD, MCI due to AD
or prodromal AD, dementia due to AD). Conceptualiz-
ing AD as a continuum may favor describing the state as
dichotomous and the stage as continuous.
Only a few years ago, diagnosis supported by bio-
marker findings (Table 1) was considered appropriate
only for research-related purposes [41]; however, there is
increasing effort to integrate biomarkers into clinical
decision-making, with several PET tracers having re-
ceived regulatory approval and CSF markers being mea-
sured with higher precision using advanced automated
systems. CSF Aβ42, total tau (t-tau), and phosphorylated
tau (p-tau) biomarkers and amyloid PET have been the
most widely studied [48, 49]. More recently, tau PET has
shown promise as a fairly specific marker of tau deposits
characteristic of AD [30, 50].
Biomarkers are now a key component of AD clinical
trials, playing a central role in selecting individuals for
whom the study treatment is most likely to be effective
and providing objective evidence of target engagement
and disease-modifying effects. Integration of biomarker
assessment into more widespread clinical use would help
with earlier and more accurate diagnosis. For example,
approximately 25% of individuals referred for clinical
trial participation with a clinical diagnosis of mild AD
dementia have been shown to be Aβ-negative [51], an
observation inconsistent with the clinico-biological con-
cept of AD, and this may be even higher in MCI due to
AD [52]. Biomarker assessment would also assist with
creation of uniform disease staging criteria for use in
clinical research and practice, to enhance communica-
tion between research and practice, and help with transi-
tion of AD treatments from research to regulatory
review to clinical practice. However, the clinical care en-
vironment has not yet evolved adequately for this to
occur. In part, this is due to challenges with cost,
standardization, accessibility, and incorporation of bio-
marker findings into patient treatment plans, but also, as
mentioned previously, currently available biomarkers
have limited ability to predict the clinical disease course.
For clinical practice, we need simpler, less invasive, and
more affordable biomarkers, as well as biomarkers that
relate to other aspects of the disease.
Role of clinical assessment
Clinical assessment still provides the central approach to
patient evaluation and should incorporate history taking
from both patients and knowledgeable informants, sup-
plemented by the use of cognitive and functional assess-
ment tools. For detection of AD in the primary care
setting, brief cognitive screening tools with adequate
sensitivity may be helpful, although careful history taking
from the individual and the family is essential. Tools that
may be considered include questionnaires that probe for
early change (e.g., Eight-item Interview to Differentiate
Aging and Dementia (AD8), Cognitive Function Instru-
ment (CFI)), brief global cognitive screens (e.g., MMSE),
and more specific tests of episodic memory impairment
indicative of hippocampal dysfunction (five-word test)
(Table 2). For formal diagnosis in specialist practice, a
more detailed clinical assessment, including neuro-
psychological testing, may be considered. Table 2 pro-
vides examples of other tools and their use within the
AD continuum. While attributes of a specific tool dictate
where it will be most useful, there is no consensus as to
which tool is most appropriate for a specific clinical en-
vironment or time point along the continuum. In the fu-
ture, we will certainly see computerized testing reaching
clinical practice as well as the general population at
large. While batteries will provide standardized and
more rapid testing, they have not yet been developed
sufficiently to be adopted widely.
In recent years, the focus in tool development has
been on more sensitive cognitive measures that are able
to detect subtle cognitive and functional impairment, to
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lower the threshold at which clinical disease can be de-
tected as well as to detect smaller changes in cognition/
function, to monitor disease progression along the con-
tinuum or therapeutic responses to interventions more
accurately. Computerized tests that can be readily ap-
plied as screening tools in the primary care setting are
also being introduced.
One key purpose of clinical assessment is to be able to
predict the temporal path of AD at the individual level;
for example, if and when MCI due to AD or prodromal
AD will progress to AD dementia. Impairment in epi-
sodic memory (i.e., the ability to learn and retain new in-
formation) is seen most commonly in individuals who
subsequently progress to a diagnosis of AD dementia
[42, 54]. Based on this, tools that assess episodic mem-
ory, both immediate and delayed recall, are valuable. De-
cline in executive functions may also flag incident AD
dementia; by contrast, change in information processing
speed/attention seems less informative [54].
The future of AD management
In the development of therapeutic interventions, there
has generally been a shift in focus from AD dementia to
MCI due to AD/prodromal AD and earlier; there is a
need for a parallel shift in the diagnostic domain, beyond
the research environment, to encourage lifestyle
modifications and participation in clinical trials. An ap-
preciation of the disease continuum engenders an
awareness of our need to consider both diagnosis and
therapies in a similar manner, along a continuum. That
is, an individual treatment or management option may
be most appropriate at a defined stage along the con-
tinuum, but its use will likely extend beyond this stage,
and there will be overlap among the various treatment
and management options such that more than one may
be appropriate at any point on the continuum. This will
be particularly relevant as new DMTs with different
mechanisms of action become available.
With DMTs, treatment earlier in the disease con-
tinuum will likely be required to achieve more disease
modification and maximize the opportunity of having an
effect through slowing decline. If and when DMTs are
approved for use, biomarker testing is likely to be central
for early and more accurate diagnosis as well as for
monitoring treatment effect. We can envision that bio-
marker findings will influence both initiation and ter-
mination of a specific treatment and may help
determine whether combination therapies are appropri-
ate and effective at the individual patient level. In par-
ticular, amyloid biomarkers will likely be necessary to
identify candidates for anti-amyloid interventions at the
predementia stages of AD.
Table 2 Examples of clinical tools used and when in the disease course they are most useful
Examples of tools
Brief tools for general setting Neuropsychological testing Clinical trials
Clinically normal/SCI CFI [55] ADCS-PACCa [38]
FCI [56]
MCI due to AD/prodromal AD MIS [57] FCSRT [58] FCSRT [58]
AD8 [59] RBANS [63] ADCOMa [60]
GPCOG [61] CVLT [66] FCI [56]
Mini-cog [62] RBANS [63]





Dementia MMSE [69] ADAS-Cog [70] ADAS-Cog [70]
ACE III [68] RBANS [63] CDR [71]
RBANS [63]
ADCS-ADL [53]
SIB [72] SIB [72]
aComposite tools—comprised of select items from existing scales
ACE III Addenbrooke’s Cognitive Examination-III, AD Alzheimer’s disease, AD8 Eight-item Informant Interview to Differentiate Aging and Dementia, ADAS-Cog Alzheimer’s
Disease Assessment Scale—cognitive subscale, ADCOM AD composite, ADCS Alzheimer’s Disease Cooperative Study, ADL activities of daily living, CDR Clinical Dementia
Rating, CFI Cognitive Function Instrument, CVLT California Verbal Learning Test, FCI Financial Capacity Instrument, FCSRT Free and Cued Selective Reminding Test,
GPCOG General Practitioner Assessment of Cognition, MCI mild cognitive impairment, MIS Memory Impairment Screen, MMSE Mini-Mental State Examination, MoCA
Montreal Cognitive Assessment, PACC Preclinical Alzheimer Cognitive Composite, RBANS Repeatable Battery for the Assessment of Neuropsychological Status, SIB Severe
Impairment Battery, SCI subjective clinical impairment
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The goal of managing any disease is primary preven-
tion and, ultimately, we anticipate blood-based assays of
amyloid dysregulation or other changes that will enable
primary prevention studies. We can envision eventual
management of such indicators of risk of amyloid accu-
mulation with secretase inhibitors, other drug therapies,
and lifestyle management to minimize reversible con-
tributors to disease.
Conclusions/discussion
While we have traditionally described AD in terms of clinic-
ally apparent stages, we now have enough understanding of
the disease course from pathophysiological, biomarker, and
clinical perspectives to appreciate the need to consider AD
as a continuum. That is, a process in which pathophysio-
logical changes accumulate and eventually culminate in
clinically apparent disease, which then progresses with grad-
ual worsening of cognitive and functional abilities; there are
no firm boundaries between the various clinical stages.
Based on what we know today, we have endeavored to de-
scribe important characteristics along the AD continuum
from disease inception to advanced clinical disease. As
noted throughout, there is considerable individual variation
along the continuum.
As efforts to detect disease earlier in the continuum and
to assess disease more accurately continue, use of bio-
markers is becoming a central facet of accurate diagnosis,
and the presence or absence of the disease may be deter-
mined using biomarkers of AD pathology. While routine
biomarker assessment of asymptomatic individuals is not
currently justified, use of well-defined biomarkers may
provide useful prognostic information in individuals with
early subjective cognitive decline, as well as help to estab-
lish therapeutic goals of clinical care.
Support for the disease continuum concept is growing,
yet how this will be successfully integrated into clinical
practice is not yet clear. For example, even with the cur-
rently available biomarkers and clinical tools, identifying
individuals who will progress along the AD spectrum, as
well as the trajectory of decline, is still fraught with chal-
lenges. Indeed, patients and caregivers only raise con-
cerns with their physician when cognitive deficits are
obvious, and this likely correlates with later stages of the
development of AD neuropathology. In the future, it is
hoped that, with better understanding of the AD con-
tinuum, earlier detection will lead to both early and ac-
curate diagnosis and intervention. By 2025 it is hoped
that effective DMTs will be approved, and biomarker as-
sessment, together with the employment of more sensi-
tive clinical tools, will become the standard of care.
Ultimately, it is predicted that we may need to perform
a detailed biomarker assessment for individualized risk
prediction to ensure treatments reach individuals at the
appropriate time to maximize effects.
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